Clinical Trial

Domperidone in Treating Patients With Gastrointestinal Disorders

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.
Protocol Amendment History 41 amendments
This ClinicalTrials.gov record has been amended 41 times since 2012-09-27; most recent amendment 2026-04-10.
Status change: Active, Not Recruiting → Recruiting 2014-11-10
Status change: Recruiting → Active, Not Recruiting 2014-02-10
Status change: Not Yet Recruiting → Recruiting 2012-10-23
Trial Details
NCT Number NCT01696734
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Digestive System Disorder, Dyspepsia, Esophagitis, Gastroesophageal Reflux Disease, Gastroparesis, Heartburn, Nausea and Vomiting
Enrollment 200 participants
Start Date 2012-10-23
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13